Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern
Actinium Pharmaceuticals, Inc. announced a KOL webinar to discuss its Iomab-ACT trial with a leading FDA approved CAR T-cell therapy at the University of Texas Southwestern. The webinar will highlight the potential billion-dollar market opportunity in lymphodepletion. Dr. Farrukh Awan will lead the trial, aiming to study Iomab-ACT with an FDA approved CAR-T cell therapy for the first time. The company presented positive phase 1 trial results at the Tandem Meetings, showing promising safety and efficacy profiles. With the expanding CAR-T market and the need for improved conditioning in cellular therapy, Iomab-ACT presents a revenue opportunity in line with the growing patient population for cell and gene therapies.
Positive phase 1 trial results with Iomab-ACT showed no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) and minimal Cytokine Release Syndrome (CRS), indicating promising safety and efficacy profiles.
The webinar will discuss the potential billion-dollar market opportunity in lymphodepletion with the expansion of the Iomab-ACT program supported by ongoing MSKCC clinical trials.
Dr. Farrukh Awan, a specialist in leukemia and lymphoma, will lead the trial to study Iomab-ACT with an FDA approved CAR-T cell therapy for the first time, aiming to improve conditioning prior to cell and gene therapies.
With the rapidly expanding CAR-T and gene therapy pipeline, Iomab-ACT presents a revenue opportunity aligned with the expected growth in the patient population for cell and gene therapies, offering potential benefits in terms of lower CRS, less ICANS, and improved overall success rates in cellular therapy.
- None.
- Dr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern and Principal Investigator for the trial to join Actinium management for webinar
- Expansion of Iomab-ACT program with commercial CAR-T supported by ongoing MSKCC clinical trial with success implying a potential billion-dollar market opportunity in lymphodepletion
- Webinar to be held on Monday, May 20th at 8:00 AM ET
Dr. Farrukh Awan specializes in the treatment of patients with leukemia and lymphoma including CAR-T therapy and bone marrow transplantation. Dr. Awan will serve as principal investigator for this study that will be led by UTSW.
To date, Iomab-ACT has been studied in a clinical trial with an investigational CD19 targeting CAR-T cell therapy developed by Memorial Sloan Kettering Cancer Center (MSKCC) under a National Institutes of Health funded grant. The trial at UTSW will be the first trial to study Iomab-ACT or any targeted radiotherapy conditioning agent with an FDA approved CAR-T therapy.
Registration for the KOL webinar can be found here or on the investor relations page of Actinium's website here.
Iomab-ACT Phase 1 CAR-T Conditioning Results
Actinium presented results from its ongoing phase 1 trial using Iomab-ACT as conditioning prior to CD19 CAR-T therapy for patients with relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) or Diffuse Large B-cell Lymphoma (DLBCL) at the Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) in February 2024. Importantly, no patients (0/4) developed immune effector cell-associated neurotoxicity syndrome (ICANS) of any grade, a major safety measure of the study and minimal Cytokine Release Syndrome (CRS). ICANS is observed in
Targeted Radiotherapy Conditioning Opportunity
The opportunity exists for better conditioning in other areas of cellular therapy, such as CAR-T as well as gene therapies. The pipeline of CAR-T and gene therapies has rapidly expanded, with the addressable patient population expected to nearly double and reach approximately 93,000 patients in the
About Actinium Pharmaceuticals, Inc.
Actinium develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidates Iomab-B (pre-BLA & MAA (EU)), an induction and conditioning agent prior to bone marrow transplant, and Actimab-A (National Cancer Institute CRADA pivotal development path), a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. Actinium holds more than 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.
For more information, please visit: https://www.actiniumpharma.com/
Forward-Looking Statements
This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.
Investors:
investorrelations@actiniumpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-announces-kol-webinar-to-highlight-recently-announced-iomab-act-trial-with-leading-fda-approved-commercial-car-t-cell-therapy-being-led-by-the-university-of-texas-southwestern-302137596.html
SOURCE Actinium Pharmaceuticals, Inc.
FAQ
What is the focus of Actinium's KOL webinar?
Who will lead the trial to study Iomab-ACT with an FDA approved CAR-T cell therapy?
What were the results of Actinium's phase 1 trial using Iomab-ACT as conditioning prior to CD19 CAR-T therapy?